AzTrials
AzTrials

Aphasia Following Cerebral InfarctionNCT07151677

Brain Stimulation Effects on Post-Stroke Fatigue and Aphasia

A study testing tDCS (active), Attention-focused sentence comprehension treatment and Sentence comprehension treatment in people with Aphasia Following Cerebral Infarction and Stroke Ischemic, run by Syracuse University at 2 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to determine if electrical brain stimulation applied to the front parts of the brain can help people who have had a stroke improve their fatigue, language, and attention. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
tDCS (active), Attention-focused sentence comprehension treatment and Sentence comprehension treatment
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
60 participants
Where
2 sitesUnited States
Study dates
4 Aug 2025to Nov 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 18 years or older.
  • No diagnosis of neurological disorder (other than stroke).
  • No diagnosis of psychiatric disorder, with the exception of anxiety and/or depression if it is managed through medication and/or behavioral intervention.
  • No seizure within the past 6 months.
  • Not pregnant.
  • Does not currently have cardiac pacemaker
Show all 16Show fewer
  • In chronic phase of recovery, defined as at least 6 months post-stroke.
  • Not undergoing speech and language therapy targeting auditory comprehension or attention for the duration of the study.
  • No metal implants in the scalp or bone in the pre-frontal area of the head.
  • No unhealed skull fractures.
  • Onset of aphasia related to single, left hemisphere, ischemic stroke.
  • Damaged brain tissue from stroke does not overlap with left hemisphere dorsolateral prefrontal cortex.
  • Mild to moderate aphasia (as measured by WAB-R **or QAB).
  • Self-report of post-stroke fatigue (as measured on SF-CAT)
  • No significant challenges with vision or hearing (with use of corrective aids if needed; eyeglasses, hearing aids).
  • Willing to allow audio-recording of study sessions.

Who cannot join

  • Younger than 18 years old.
  • Diagnosis or history of neurological disorder other than stroke.
  • Diagnosis or history of psychiatric disorder with the exception of anxiety and/or depression if it is managed through medication and/or behavioral intervention.
  • History of seizures within the past 6 months.
  • Pregnant.
  • Currently has cardiac pacemaker
Show all 16Show fewer
  • <6 months post-stroke (however, if this is only exclusionary criterion met, participant can be re-evaluated at the 6-month mark if still interested in the study)
  • Currently undergoing speech and language therapy targeting auditory comprehension or attention.
  • Metal implants in the scalp or bone in the pre-frontal area of the head.
  • Currently has an unhealed skull fracture.
  • Onset of aphasia related to etiology other than ischemic left hemisphere stroke.
  • Damaged brain tissue significantly overlaps with left hemisphere dorsolateral prefrontal cortex.
  • No aphasia or severe aphasia (as measured by WAB-R **or QAB).
  • Does not report experience of post-stroke fatigue (as measured on SF-CAT)
  • Significant challenges with vision and/or hearing (even with use of corrective aids).
  • Unwilling to allow audio-recording of study sessions.

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Ellyn Riley contact

315-443-8688

aphasia@syr.edu

United States2 sites, 2 recruiting
  • University of Michigan

    Ann Arbor, Michigan, 48109

    Carol Persad, 734-615-8112, cpersad@umich.edu

    Not yet recruiting
  • Syracuse University

    Syracuse, New York, 13244

    Ellyn Riley, 315-443-8688, aphasia@syr.edu

    Recruiting

Other trials in United States

About this study

Official title: Pre-Frontal tDCS as a Novel Intervention to Reduce Effects of Post-Stroke Fatigue While Improving Language and Attention in Aphasia

The goal of this clinical trial is to determine if electrical brain stimulation applied to the front parts of the brain can help people who have had a stroke improve their fatigue, language, and attention. The main question it aims to answer is:

  • Does transcranial direct current stimulation (tDCS) administered to the pre-frontal areas of the brain improve post-stroke fatigue and aphasia?
  • What kinds of participant characteristics are associated with better improvement of post-stroke fatigue and aphasia?

Researchers will compare active electrical stimulation to sham stimulation to see if the active stimulation does a better job at reducing fatigue and language deficits after stroke. Participants will be asked to complete fatigue, language, and cognitive testing before and after receiving 10 sessions of tDCS plus speech and language therapy.

Being tested
tDCS (active), Attention-focused sentence comprehension treatment, Sentence comprehension treatment, tDCS (sham)
Keywords
aphasia, fatigue, post-stroke fatigue, tDCS, brain stimulation, language treatment, language therapy, speech therapy, speech-language therapy
Medical subject headings
Ischemic Stroke, Fatigue, Aphasia, Communication Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • tDCS (active)Device

    Also called transcranial direct current stimulation

    The investigators will administer active tDCS to left dorsolateral prefrontal cortex (DLPFC) during 10 sessions of behavioral treatment. For active tDCS, the current will slowly be increased to 2mA and applied for 20 minutes.

  • Attention-focused sentence comprehension treatmentBehavioural

    This is a specific type of speech-language therapy that focuses on simultaneously improving auditory comprehension and behavioral attention. Participants will receive 10 sessions of this treatment.

  • Sentence comprehension treatmentBehavioural

    This is a specific type of speech-language therapy that focuses on improving auditory comprehension . Participants will receive 10 sessions of this treatment.

  • tDCS (sham)Device

    Also called transcranial direct current stimulation

    The investigators will administer sham tDCS to left dorsolateral prefrontal cortex (DLPFC) during 10 sessions of behavioral treatment. For sham tDCS, the current will slowly be increased to 2mA over the course of 30 seconds and then immediately ramped back down to zero.

Study groups in NCT07151677
Study groupRoleWhat they receive
active tDCS plus attention-focused language treatmentExperimentalactive tDCS and attention focused language treatment will be administered
Receives: Device: tDCS (active); Behavioral: Attention-focused sentence comprehension treatment
active tDCS plus sentence picture matching treatmentActive comparatoractive tDCS and sentence picture matching treatment will be administered
Receives: Device: tDCS (active); Behavioral: Sentence comprehension treatment
sham tDCS plus attention-focused language treatmentSham comparatorsham tDCS and attention focused language treatment will be administered
Receives: Behavioral: Attention-focused sentence comprehension treatment; Device: tDCS (sham)
sham tDCS plus sentence picture matching treatmentSham comparatorsham tDCS and sentence picture matching treatment will be administered
Receives: Behavioral: Sentence comprehension treatment; Device: tDCS (sham)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Fatigue Interference and Severity Scale for Aphasia (FISS-A)

    Scale from 1-7, higher scores mean more significant fatigue

    Measured: baseline; within 1 week following the final treatment session; 3- month follow-up

Secondary outcomes (3)
  1. Continuous Performance Test (CPT)

    Measured: baseline; within 1 week following the final treatment session; 3- month follow-up

  2. Attention Network Test (ANT)

    Measured: baseline; within 1 week following the final treatment session; 3- month follow-up

  3. Sentence comprehension task

    Measured: baseline; within 1 week following the final treatment session; 3- month follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Sep 2025
  2. Study start4 Aug 2025
  3. Primary completionSep 2029 (estimated)
  4. Study completionNov 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Factorial
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07151677
Sponsor's protocol ID
1R01DC021677-01A1
Other IDs
1R01DC021677-01A1
Status last verified
Sep 2026
First submitted
18 Aug 2025
Last updated
30 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Yes: Data generated for this project will include participant demographic data, medical information related to the participant's stroke (e.g., date of stroke onset, lesion location), standardized test scores from language and cognitive tests (e.g., Western Aphasia Battery), and outcome measure data. All data will be de-identified.

Questions about this trial

What is this clinical trial studying?

A study testing tDCS (active), Attention-focused sentence comprehension treatment and Sentence comprehension treatment in people with Aphasia Following Cerebral Infarction and Stroke Ischemic, run by Syracuse University at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 16 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 30 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Ellyn Riley (315-443-8688, aphasia@syr.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Fatigue Interference and Severity Scale for Aphasia (FISS-A) (time frame: baseline; within 1 week following the final treatment session; 3- month follow-up). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Sep 2026; AzTrials last refreshed its copy on 26 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in